Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene forecasts 2012 growth based on strong performance

Celgene forecasts 2012 growth based on strong performance

10th January 2012

Celgene has outlined its forecasts for positive growth over the next 12 months after achieving a record-breaking financial performance during 2011.

The pharmaceutical company has issued guidance which targets revenue growth of around 15 percent during 2012, to a total of between $5.4 and $5.6 billion (3.49 to 3.61 billion pounds).

This comes after the firm reported year-on-year growth of 34 percent during 2011, reaching a total of $4.8 billion, thanks to strong double-digit sales increases for drugs such as Revlimid and Vidaza.

Revlimid sales are expected to continue to expand during 2012, while notable progress has been made in the last year across all three of Celgene's therapeutic areas of inflammation and immunology, haematology and oncology.

Bob Hugin, Celgene's chairman and chief executive officer, said: "The 2012 guidance reflects our confidence in the continued operational momentum in executing our business plan by our global teams."

Earlier this month, the company improved its UK and Ireland corporate infrastructure through the appointment of Dr David Gillen as medical director.ADNFCR-8000103-ID-801259764-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.